Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
393 studies found for:    biogen | biogen
Show Display Options
Rank Status Study
1 Recruiting Biogen Multiple Sclerosis Pregnancy Exposure Registry
Conditions: Multiple Sclerosis;   Exposure During Pregnancy
Interventions: Drug: dimethyl fumarate;   Drug: Peginterferon beta-1a;   Drug: Dalclizumab High Yield Process
2 Completed Open-Label Safety Extension Study of Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Avonex)
3 Terminated 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
Condition: Rheumatoid Arthritis
Intervention: Biological: Baminercept alfa (BG9924)
4 Terminated BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)
Condition: Rheumatoid Arthritis
Intervention: Drug: BG9924
5 Completed A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers
Condition: Healthy
Interventions: Drug: dimethyl fumarate - Reference form;   Drug: dimethyl fumarate - Test form
6 Completed ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Condition: Multiple Sclerosis
Intervention:
7 Completed Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Condition: Multiple Sclerosis
Intervention: Drug: low immunogenic interferon-beta-1a
8 Recruiting An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine
9 Completed Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
10 Completed BG9928 in Subjects With Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: BG9928
11 Completed Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
Condition: Multiple Sclerosis
Interventions: Drug: Interferon beta-1a;   Device: Single-use autoinjector
12 Completed Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Avonex)
13 Completed A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers
Condition: Multiple Sclerosis
Interventions: Drug: Serum containing Avonex;   Drug: Serum Free Avonex
14 Completed Immunogenicity and Safety Study of Serum-Free Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a
15 Completed Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a
16 Terminated How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: Interferon beta-1a
17 Completed GER-009-06-AVX Early Therapy in Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention:
18 Completed Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
19 Completed Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
Conditions: Tumors;   Lymphoma
Intervention: Drug: CNF2024
20 Completed Open-Label Natalizumab Safety Extension Study
Condition: Multiple Sclerosis
Intervention: Drug: Natalizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.